Third Department of Urology, School of Medicine, University of Athens, Attiko Hospital, Athens, Greece.
Department of Urology, Cambridge University Hospitals NHS Trust, Cambridge, UK.
Low Urin Tract Symptoms. 2022 Jan;14(1):57-63. doi: 10.1111/luts.12410. Epub 2021 Sep 2.
To determine the effectiveness and safety of intravesical hyaluronic acid (HA) in symptomatic women with trigonitis and to correlate the severity of symptoms with the endoscopic and histological findings.
Thirty-seven patients (aged 20-46 years) were enrolled. All patients had cystoscopy and biopsy of the bladder trigone followed by intravesical instillations of sodium HA once weekly for 10 weeks and then once monthly for the next 10 months. Clinical response was evaluated by Pain and Urgency/Frequency (PUF) Symptom Scale, visual analog scale (VAS) for pain and urgency and functional bladder capacity. A repeat cystoscopy and biopsy were performed at the end of the treatment. Symptoms and cystoscopy and pathological findings were compared before and after treatment.
The average initial score for pain was reduced from 5.5 to 2.8 (P < 0.001) at 10 weeks and further to 2.4 (P < 0.001) at 12 months and the score for urgency from 6.9 to 3.8 (P < 0.001) and further to 3.3 (P < 0.001). The average PUF score initially decreased from 20.5 to 12.1 (P < 0.001) and then further to 10.1 (P = 0.21). The mean functional bladder capacity increased from 125 to 204 mL (P < 0.001). No association was found between baseline PUF score and cystoscopy findings (P = 0.87). The PUF score was not changed significantly between patients with improved cystoscopy and those with stable findings (P = 0.74). No significant changes were reported between initial and final biopsies.
Intravesical HA appeared to be effective and well tolerated, although a clear relationship between symptoms and trigonitis was not confirmed.
确定膀胱内透明质酸(HA)在患有三角区膀胱炎症状的女性中的有效性和安全性,并将症状严重程度与内镜和组织学发现相关联。
共纳入 37 名(年龄 20-46 岁)患者。所有患者均接受膀胱三角区膀胱镜检查和活检,随后每周进行一次膀胱内 HA 灌注,共 10 周,然后每月进行一次,共 10 个月。临床反应通过疼痛和尿急/频率(PUF)症状量表、疼痛和尿急的视觉模拟量表(VAS)以及功能性膀胱容量进行评估。在治疗结束时进行重复膀胱镜检查和活检。比较治疗前后的症状、膀胱镜和病理发现。
疼痛的平均初始评分从 5.5 分降至 10 周时的 2.8 分(P<0.001),进一步降至 12 个月时的 2.4 分(P<0.001),尿急的评分从 6.9 分降至 3.8 分(P<0.001),进一步降至 3.3 分(P<0.001)。PUF 评分的平均初始评分从 20.5 分降至 12.1 分(P<0.001),然后进一步降至 10.1 分(P=0.21)。平均功能性膀胱容量从 125 毫升增加到 204 毫升(P<0.001)。在基线 PUF 评分和膀胱镜检查结果之间未发现相关性(P=0.87)。在膀胱镜检查结果改善和稳定的患者之间,PUF 评分没有显著变化(P=0.74)。初始和最终活检之间未报告显著变化。
膀胱内 HA 似乎有效且耐受性良好,尽管未证实症状与三角区炎之间存在明确关系。